Verici Dx Plc (63V) AI Stock Analysis

Verici Dx Plc

(Frankfurt:63V)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Revenue GrowthRapid revenue expansion indicates increasing commercial adoption of Verici Dx’s transplant-focused diagnostic products. If sustained, the larger revenue base can improve operating leverage, support broader clinical uptake, and create a stronger foundation for future profitability.

Negative Factors

Persistent Net LossesSizable and persistent net losses show that revenue growth has not yet translated into a sustainable earnings model. The widening 2025 loss increases the distance to profitability and may constrain internal reinvestment, making future financial progress dependent on stronger operating leverage.

Verici Dx Plc (63V) vs. iShares MSCI Germany ETF (EWG)

Market Cap: EUR 3.84M
Dividend Yield: ―
Average Volume (3M): ―
Price to Earnings (P/E): -0.6
Beta (1Y): -2.41
Revenue Growth: 72.40%
EPS Growth: 84.78%
Country: Germany
Employees: 18
Sector: Healthcare
Sector Strength: 51
Industry: Medical - Diagnostics & Research

Verici Dx Plc Business Overview & Revenue Model

Company Description

Verici Dx plc is an immuno-diagnostics company primarily focused on the kidney transplantation sector. The firm specializes in creating both predictive and diagnostic assays for patients who have undergone kidney transplants. Its development pipeline...

Verici Dx Plc Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

DE:63V against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
GB:EKF	64Neutral	GBP 102.71M	41.38	3.58%	―	2.26%	-57.04%
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
GB:GDR	49Neutral	GBP 15.65M	-0.89	-1044.57%	―	65.60%	74.84%
GB:ABDX	46Neutral	GBP 22.75M	-16.36	-34.31%	―	30.42%	43.16%
GB:OBD	40Underperform	GBP 14.45M	-0.27	-451.74%	―	33.37%	86.41%
GB:RENX	40Underperform	GBP 36.54M	-3.44	675.00%	―	―	―

* Healthcare Sector Average

Performance Comparison

DE:63V and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
DE:63V	Verici Dx Plc	0.02	0.01	53.85%
GB:EKF	EKF Diagnostics Holdings	24.00	-2.20	-8.40%
GB:GDR	Genedrive plc	0.97	0.01	1.25%
GB:OBD	Oxford BioDynamics	0.11	-0.21	-66.56%
GB:RENX	Renalytix Plc OTC	5.45	-1.93	-26.15%
GB:ABDX	Abingdon Health PLC	9.00	2.75	44.00%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Verici Dx Plc AI Stock Analysis